Dartmouth’s RADIUS telemedicine program is using gastroenterology advanced practice providers (APPs) to extend specialized inflammatory bowel disease (IBD) care to rural patients across New England. The model connects patients with an IBD specialist and a multidisciplinary team that includes a psychologist, dietitian, pharmacist, and nurse coordinator, while APPs closer to home manage ongoing care. This reduces the need for patients to travel long distances for specialist consultations and advanced treatment decisions. As of June 2026, the program had cared for nearly 500 patients, with more than 80% starting optimized or advanced therapies. The article highlights how APPs have developed IBD…
Author: Abhay Panchal
A UK-wide analysis of nearly 16,000 IBD surveillance endoscopies performed in 2024 has identified opportunities to improve colorectal cancer detection in patients with Crohn’s disease and ulcerative colitis. The study, involving 4,669 endoscopists across approximately 65% of UK endoscopy units, found that polyp detection was associated with three factors: regular experience performing IBD examinations, more time allocated to procedures, and the use of dye to improve mucosal visibility. The analysis also revealed that fewer than one in five endoscopists performed IBD surveillance examinations at least monthly, although this group carried out 57% of all procedures. Researchers suggest that more consistent…
Blue Cross and Blue Shield of Texas will stop offering Medicare Advantage (MA) plans after this year. The insurer offered plans in 227 Texas counties in 2026, according to Becker’s Payer Issues. Its parent company, Health Care Service Corp. (HCSC), will keep offering HealthSpring MA plans in 47 Texas counties. Open enrollment for 2027 coverage runs through Dec. 7. Nationally, UnitedHealth Group is leaving 228 counties and entering nine. Humana is leaving 62 and entering four. HCSC is leaving 498 counties and entering none, and Centene is leaving 359 and entering 15. Those figures come from a KFF analysis of…
Robotic colonoscopy has been in development for more than three decades, with several systems receiving FDA clearance. However, despite advances in robotic surgery, robotic endoscopy platforms have yet to achieve widespread clinical adoption. This narrative review examines existing and experimental robotic colonoscopy technologies, exploring why earlier systems struggled to gain traction and what could shape the next generation of devices. The review highlights the potential of robotic platforms to advance minimally invasive colonoscopy, but also underscores the technical and practical limitations that have restricted their use. Several previously cleared systems were ultimately withdrawn from the market, illustrating the gap between…
The FDA has expanded its approval of risankizumab (Skyrizi) to include a subcutaneous induction regimen for adults with moderately to severely active Crohn’s disease. Previously, patients had to receive induction intravenously before transitioning to subcutaneous maintenance. The new approval allows patients to begin treatment at home using an on-body injector, offering greater flexibility in how therapy is initiated. The decision was supported by the Phase 3 AFFIRM trial, which evaluated 289 adults with moderate-to-severe Crohn’s disease. At week 12, patients receiving subcutaneous risankizumab achieved higher rates of clinical remission than those receiving placebo (55% vs. 29.6%). Endoscopic response was also…
Grail’s Galleri blood test screens for multiple cancer types using a single blood draw, analyzing DNA fragments for cancer signals and predicting their likely origin. As the test moves closer to a potential FDA decision, five cancer specialists highlighted its promise for detecting cancers that lack established screening methods, alongside concerns about sensitivity, follow-up testing, and whether earlier detection improves survival. In the PATHFINDER 2 study, Galleri’s positive predictive value was approximately 62%, meaning positive results were confirmed as cancer in about six out of 10 cases. Reported specificity was 99.6%, while the test correctly predicted the cancer’s origin in…
A multinational study published in Clinical Gastroenterology and Hepatology found that abdominal pain in irritable bowel syndrome (IBS) is closely associated with daily-life factors, including emotional state, eating, and perceived environmental comfort. The study included 360 adults with Rome IV–defined IBS across seven European countries. Participants used a smartphone app to report symptoms and potential triggers 10 times daily over seven days. Higher positive affect and greater environmental comfort were associated with lower abdominal pain, while negative affect and eating were associated with increased pain. However, most associations weakened substantially after researchers adjusted for disease severity, anxiety, depression, fatigue, and…
Takeda announced positive results from VERDICT, a Phase 4 randomized trial evaluating treat-to-target strategies with vedolizumab (Entyvio) in adults with moderate to severe ulcerative colitis (UC). The study found that targeting corticosteroid-free disease clearance—combining symptomatic, endoscopic, and histologic remission—was associated with a 67% lower hazard of a first UC-related complication compared with targeting symptomatic remission alone (hazard ratio 0.33; 95% CI, 0.17–0.67; P = 0.0014). The trial enrolled 672 patients assigned to three increasingly stringent treatment targets: symptomatic remission, symptomatic plus endoscopic remission, or combined symptomatic, endoscopic, and histologic remission. Treatment was adjusted using predefined vedolizumab-based algorithms. Among patients who…
Physician practices face mounting financial pressures as operating costs rise and Medicare physician payments decline in inflation-adjusted terms. The percentage of physicians who own their practices fell from 60% in 2012 to 44% in 2024, while 56% now work for hospitals, health systems, or corporate entities. In this Industry Voices article, legal, clinical, and financial experts outline alternatives to private equity for practices seeking sustainable growth. The authors identify four strategies: maintaining the existing practice model while making targeted improvements or acquiring smaller practices; expanding independently through financing, ancillary services, extended hours, competitive staffing, outsourced administrative functions, and AI-enabled tools;…
An updated version of Freenome’s SimpleScreen colorectal cancer (CRC) blood test demonstrated improved sensitivity for detecting advanced precancerous lesions (APLs), according to findings presented at the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting. At 90% specificity, the updated test achieved 80.4% sensitivity for CRC and increased APL detection sensitivity from 13.7% to 18.2%. Sensitivity for APLs with high-grade dysplasia rose from 30.5% to 41.9%. The analysis included 9,131 samples from average-risk populations, drawing on the PREEMPT CRC trial and additional previously tested samples. Cancer detection sensitivity varied by stage, reaching 52.1% for stage I, 100% for stage II,…
